Biology & Diagnosis: Decoding the Testing

While a diagnosis of Corticobasal Syndrome (CBS) describes what is happening on the outside, understanding the biology of the disease helps explain why the symptoms are so unique and why a definitive answer can be so elusive. Because there is currently no single “litmus test” for the underlying disease—Corticobasal Degeneration (CBD)—doctors must act as detectives, using a combination of clinical rules and imaging to piece the puzzle together ^[1][2].

The Biology: 4R Tauopathy

At the microscopic level, CBD is classified as a 4-repeat (4R) tauopathy ^[3].

Inside every healthy brain, a protein called tau helps stabilize the internal structure of nerve cells. In CBD, this 4-repeat tau protein isoform accumulates abnormally in specific cell types, leading to neuronal injury ^[4]. These aggregates injure the brain’s communication lines and eventually cause nerve cells to die ^[5].

CBD is specifically a “4R” disease, which distinguishes it from Alzheimer’s (which has a mix of tau types and amyloid) or Pick’s disease (which has “3R” tau) ^[3]. This abnormal accumulation is typically associated with three key areas ^[6][5]:

• Frontoparietal Cortex: The outer layer of the brain responsible for planning movements and processing sensations.
• Basal Ganglia: Deep brain structures that act as a “switchboard” for smooth physical movement.
• Substantia Nigra: The area that produces dopamine; damage here is what causes the symptoms that look like Parkinson’s disease.

The 2013 Armstrong Criteria

Because many different diseases can cause “Corticobasal Syndrome” (CBS), an international team of experts led by Dr. Armstrong created a framework in 2013 to help doctors identify who likely has the actual CBD pathology ^[1].

This clinicopathologic research framework recognizes that CBD doesn’t always look the same. It identifies four different “phenotypes” or clinical patterns ^[1][7]:

1. Corticobasal Syndrome (CBS): The classic “one-sided” stiffness and “alien limb” symptoms.
2. Frontal Behavioral-Spatial Syndrome (FBS): Primarily involves changes in personality, “filter,” or the ability to navigate physical space.
3. Nonfluent/Agrammatic Primary Progressive Aphasia (naPPA): Primarily involves a struggle to form sentences or use correct grammar, even if the person knows what they want to say.
4. Progressive Supranuclear Palsy Syndrome (PSPS): Symptoms that mimic another rare disease (PSP), involving balance issues and difficulty moving the eyes up and down.

Under these rules, a doctor may label a diagnosis as Probable CBD (more strictly defined, often used for research) or Possible CBD (a broader category used when the symptoms are suggestive but not definitive) ^[1]. Explicitly, these criteria use “probable” or “possible” as part of a broader clinical assessment; they do not definitively confirm CBD pathology in life.

Why Imaging is a “Rule-Out” Tool

One of the most frustrating aspects of this diagnosis is that an MRI or PET scan cannot currently identify 4R tau clumps directly in routine clinical practice ^[8]. Instead, specialists use imaging primarily to rule out other conditions or find supportive evidence:

• MRI (Structural Imaging): Doctors look for asymmetry, where one side of the brain (the front and middle sections) is visibly smaller or more “shrunken” than the other ^[5][9]. While asymmetric atrophy supports CBS, it is neither required nor highly specific. If they see significant shrinkage in the midbrain instead, they might suspect PSP ^[9].
• FDG-PET (Metabolic Imaging): This scan shows how the brain uses glucose (energy). In CBD, the energy use is typically lower in the motor and sensory areas on one side ^[10]. If the energy loss is in the back of the brain, it may point toward Alzheimer’s disease ^[11].
• Amyloid/Tau Biomarkers: These are tests of the spinal fluid or special PET scans that look for the specific markers of Alzheimer’s disease. If these are “negative,” it makes Alzheimer’s pathology much less likely, though it does not automatically establish “pure CBD” ^[12][13].

Tests Your Doctor May Consider

Because of the complexity, a “wait and see” approach is common, but specialists use a variety of tools. The following tests are selectively used based on their purpose, limitation, and likelihood of changing management:

• Movement Disorder Specialist Exam: A physical exam specifically focused on eye movements, gait, and “atypical” parkinsonian signs ^[14].
• Formal Praxis Assessment: Specialized testing to see if the brain can “plan” movements (e.g., mimicking gestures or using a tool like a comb) ^[15].
• High-Resolution MRI: To look for supportive patterns like asymmetric brain shrinkage ^[9].
• Neuropsychological Testing: A detailed “brain map” of memory, language, and spatial abilities to distinguish between different phenotypes ^[14].
• Dopamine Imaging (DaTscan/FDOPA): This scan detects presynaptic dopaminergic loss. It confirms a deficit in the dopamine system but generally cannot reliably distinguish CBD from Parkinson’s or PSP ^[16][17].
• Biomarker Screening: Testing for Alzheimer’s markers (amyloid/tau) in the blood, spinal fluid, or via PET scan to rule out Alzheimer’s disease as the cause ^[12].
• Genetic Screening: Genetic testing (for mutations like MAPT, GRN, or C9orf72) is not routine for most sporadic CBS. It is selectively used—such as for patients with young onset or strong family history—and should involve genetic counseling ^[18].

While these tests help narrow the field, a definitive diagnosis of Corticobasal Degeneration can still only be confirmed by examining the brain tissue after death ^[19][20]. Until then, the goal of the workup is to provide the most accurate “clinical best guess” to guide symptom management.